<?xml version="1.0" encoding="UTF-8"?>
<p>No specific treatment for COVID-19 is yet known, but the search for a suitable drug is well under way. On 11 March 2020, 84 trials were listed on 
 <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">www.clinicaltrials.gov</ext-link> under the keyword “COVID-19.” The substances under investigation range from immunomodulatory approaches with immunoglobulins, interferon, thalidomide, and glucocorticoids to treatment with virustatics such as oseltamivir, darunavir, and umifenovir, which was developed in Russia for the treatment of influenza (
 <xref rid="T1" ref-type="table">table 1</xref>). In view of the possibility of resistance developing, it would certainly be desirable to have more than one option for treatment. On the basis of experience with antiviral therapeutics to date, it is to be expected that evolutionary mutations of the viral genome will endow SARS-CoV-2 with new properties, including resistance to certain substances.
</p>
